The Food and Drug Administration (FDA)'s Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Bethesda, Md., on Feb. 25, 2011, to select the influenza viruses for the composition of the influenza vaccine for the 2011-2012 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2010-2011 vaccines, and the availability of candidate strains and reagents.
The committee recommended that vaccines to be used in the 2011-2012 influenza season in the U.S. contain the following:
- A/California/7/09 (H1N1)-like virus*
- A/Perth /16/2009 (H3N2)-like virus
- B/Brisbane/60/2008-like virus
*A/California/7/09 (H1N1)-like virus is the pandemic (H1N1) 2009 influenza virus
This years vaccine for the United States includes the same viruses that were used for the 2010-2011 influenza season and the influenza vaccine composition is identical to that recommended by the World Health Organization on Feb. 17, 2011, for the Northern Hemisphere's 2011-2012 influenza season.
-
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.